Trials / Terminated
TerminatedNCT04791514
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treprostinil Palmitil | Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler |
Timeline
- Start date
- 2022-03-29
- Primary completion
- 2022-08-26
- Completion
- 2022-08-26
- First posted
- 2021-03-10
- Last updated
- 2023-09-22
- Results posted
- 2023-09-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04791514. Inclusion in this directory is not an endorsement.